Ultragenyx Pharmaceutical (RARE)
(Delayed Data from NSDQ)
$58.75 USD
-0.03 (-0.05%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $58.79 +0.04 (0.07%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth D Momentum D VGM
Price, Consensus and EPS Surprise
RARE 58.75 -0.03(-0.05%)
Will RARE be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for RARE based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for RARE
Ultragenyx (RARE) Q2 Loss Narrower Than Expected, Revenues Up
Compared to Estimates, Ultragenyx (RARE) Q2 Earnings: A Look at Key Metrics
RARE: What are Zacks experts saying now?
Zacks Private Portfolio Services
Ultragenyx (RARE) Reports Q2 Loss, Tops Revenue Estimates
Ultragenyx (RARE) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
Ionis (IONS) Up 6% on Detailed Data From Angelman Drug Study
Other News for RARE
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Tactical Resources Rises Amid Global REE Disruptions
Tactical Resources Strengthens Position Amid Rare Earth Elements Market Disruptions
Ultragenyx Pharmaceutical (RARE) Gets a Buy from Bank of America Securities
Tracking Baker Brothers Portfolio - Q2 2024 Update